1. (Cancelled)

2. (Cancelled)

3. (Previously Amended) A compound selected from the group consisting of:

(1α, 5α, 6α)-6N-[3-benzyl-3-azabicyclo[3.1.0]hexyl]-3-methyl-4-oxo-α-phenyl-4H-1-benzopyran-8-carboxamide (Compound No. 1);

(1α, 5α, 6α)-6N-[3-(4-cyanobenzyl)-3-azabicyclo[3.1.0]hexyl]-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxamide (Compound No. 2);

(1α,5α, 6α)-N-[3-benzyl-3-azabicyclo [3.1.0] hexyl-6-(aminomethyl)-yl]-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxamide (Compound No. 3);

(1α,5α,6α)-N-[3-(4-methyl-3-pentyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxamide (Compound No. 4); and

N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-1-(aminomethyl)-yl]-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxamide (Compound No. 5).

4. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound as defined in claim ~~1, 2 or~~ 3 together with pharmaceutically acceptable carriers, excipients, or diluents.

5. (Currently Amended) A method for treatment of an animal or a human suffering from a disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is urinary incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel syndrome, obesity, diabetes, and gastrointestinal hyperkinesis, comprising administering to said animal or human, a therapeutically effective amount of a compound of claim 3 ~~having the structure of Formula I,~~



Formula I

~~or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N oxides, prodrugs, metabolites, wherein:~~

~~W represents $(CH_2)_p$, where p represents 0 to 1;~~

~~X represents an oxygen, sulphur, nitrogen or no atom;~~

~~Y represents CHR_1CO, wherein R_1 represents hydrogen or methyl or $(CH_2)q$ wherein q represents 0 to 4;~~

~~Z represents oxygen, sulphur, NR_2, wherein R_2 represents hydrogen, C_{1-6} alkyl;~~

~~Q represents $(CH_2)n$ wherein n represents 0 to 4, or CHR_3 wherein R_3 represents H, OH, C_{1-6} alkyl, alkenyl, alkoxy or CH_2CHR_4 wherein R_4 represents H, OH, lower alkyl (C_1-C_4) or lower alkoxy (C_1-C_4);~~

~~R_5 and R_6 are independently selected from COOH, H, CH_3, $CONH_2$, NH_2, CH_2NH_2;~~

~~R_7 represents C_1-C_{15} saturated or unsaturated aliphatic hydrocarbon groups in which any 1 to 6 hydrogen atoms may be substituted with the group independently selected from halogen, arylalkyl, arylalkenyl, heteroarylalkyl or heteroarylalkenyl having 1 to 2 hetero atoms selected from a group consisting of nitrogen, oxygen and sulphur atoms with option that any 1 to 3 hydrogen atoms on the ring in said arylalkyl, arylalkenyl, hetero arylalkenyl group may be substituted with lower alkyl (C_1-C_4), lower perhalo alkyl (C_1-C_4), cyano, hydroxyl, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (C_1-C_4), lower perhaloalkoxy (C_1-C_4); unsubstituent amino, N-lower alkylamino (C_1-C_4), N-lower alkylamino carbonyl (C_1-C_4);~~

~~Aryl rings may be unsubstituted or substituted by R_8 and R_9, in which any one to three substituents may be independently selected from lower alkyl (C_1-C_4), trifluoromethyl, cyano, hydroxy, nitro, lower alkoxy (C_1-C_4), amino or lower alkylamino; and~~

~~R_{10} represents aryl which may be substituted with one or more substituent.~~

6. (Currently Amended) The method according to claim 5 for treatment of an animal or a human suffering from a disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is urinary incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel syndrome, obesity, diabetes, and gastrointestinal hyperkinesis, comprising administering to said animal or human, a therapeutically effective amount of a compound of claim 3 ~~having the structure of Formula II, and its pharmaceutically acceptable salts, pharmaceutically acceptable, esters, enantiomers, diastereomers, prodrugs, polymorphs, or metabolites, wherein R_3, R_5, R_{10}, R_7, W,X,Y,Z,Q are as defined for Formula I~~.



Formula II

7.– 8. (Previously Cancelled).

9. (Currently Amended) The method for treatment ~~or prophylaxis~~ of an animal or a human suffering from a disease or disorder of the respiratory, urinary, and gastrointestinal systems, wherein the disease or disorder is urinary incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic obstructive pulmonary

disorders (COPD), pulmonary fibrosis, irritable bowel syndrome, obesity, diabetes, and gastrointestinal hyperkinesis, comprising administering to said animal or human, a therapeutically effective amount of the pharmaceutical composition according to claim 4.

10. (Previously Cancelled).

11.– 18. (Cancelled).